110
Participants
Start Date
March 31, 2007
Primary Completion Date
February 28, 2010
Study Completion Date
September 30, 2012
Pemetrexed
pemetrexed 500 mg/m2
Gemcitabine
gemcitabine 1500 mg/m2
Bevacizumab
bevacizumab 10mg/kg bevacizumab 15mg/kg
Carboplatin
carboplatin AUC=5
Cancer Care of Western North Carolina, Asheville
Spartanburg Regional Medical Center, Spartanburg
Wellstar Cancer Research, Marietta
Northeast Georgia Medical Center, Gainesville
Watson Clinic Center for Cancer Care and Research, Lakeland
Florida Cancer Specialists, Fort Myers
Northeast Alabama Regional Medical Center, Anniston
Tennessee Oncology, PLLC, Nashville
Associates in Hematology Oncology, Chattanooga
Chattanooga Oncology Hematology Associates, Chattanooga
Consultants in Blood Disorders and Cancer, Louisville
Graves-Gilbert Clinic, Bowling Green
Oncology Hematology Care, Cincinnati
Providence Medical Group, Terre Haute
Grand Rapids Clinical Oncology Program, Grand Rapids
Methodist Cancer Center, Omaha
NEA Baptist Clinic, Jonesboro
Mercy Hospital, Portland
Collaborators (1)
Genentech, Inc.
INDUSTRY
Eli Lilly and Company
INDUSTRY
SCRI Development Innovations, LLC
OTHER